APA

Ribrag V., Nasr F., Bouhris J. H., Bosq J., Brault P., Girinsky T., Cosset J. M., Munck J. N., Corti C., Decaudin D., Pico J. L., Hayat M. & Carde P. (19980806). VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. : Bone marrow transplantation.

Chicago

Ribrag V, Nasr F, Bouhris J H, Bosq J, Brault P, Girinsky T, Cosset J M, Munck J N, Corti C, Decaudin D, Pico J L, Hayat M and Carde P. 19980806. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. : Bone marrow transplantation.

Harvard

Ribrag V., Nasr F., Bouhris J. H., Bosq J., Brault P., Girinsky T., Cosset J. M., Munck J. N., Corti C., Decaudin D., Pico J. L., Hayat M. and Carde P. (19980806). VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. : Bone marrow transplantation.

MLA

Ribrag V, Nasr F, Bouhris J H, Bosq J, Brault P, Girinsky T, Cosset J M, Munck J N, Corti C, Decaudin D, Pico J L, Hayat M and Carde P. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. : Bone marrow transplantation. 19980806.